Modular Medical Completes MODD1 Cartridge Production, Prepares for Pivot Launch

Modular Medical has completed its MODD1 cartridge production run and is converting its manufacturing line to produce its Pivot product. The Pivot will be the first tubeless, removable 3 milliliter patch pump available to consumers if cleared by the FDA. The company expects to submit Pivot for clearance in October 2025 and notes its simple, low-cost platform was designed for high-volume manufacturing.

Modular Medical, Inc. (Nasdaq:MODD), a leading developer of insulin delivery technology, has successfully completed the production run of its MODD1 cartridges, marking a significant milestone in the company's journey towards revolutionizing diabetes care. The company, which specializes in user-friendly and affordable insulin delivery solutions, has now begun converting its manufacturing line to produce its next-generation product, the Pivot.

The MODD1 cartridge production run resulted in the manufacture of over 6,000 cartridges, a testament to Modular Medical's operational efficiency and commitment to quality. Jeb Besser, CEO of Modular Medical, expressed his pride in the successful validation of the manufacturing process and the production of human-use cartridges, stating, "I want to congratulate our operational team for the successful validation of our MODD1 manufacturing process and production of human-use cartridges."

The company is now focused on converting its manufacturing line to produce cartridges for the Pivot product. The Pivot is set to be the first tubeless, removable 3 milliliter patch pump available to consumers once it is cleared by the U.S. Food and Drug Administration (FDA). Modular Medical expects to submit the Pivot product for FDA clearance in October 2025.

The Pivot is designed to offer a significant advantage in the pump space by providing a simple, low-cost platform designed for high-volume manufacturing. This feature is particularly important given the much higher volumes required for a patch pump compared to traditional insulin pumps.

Modular Medical's mission is to improve access to the highest standard of glycemic control for people with diabetes, moving beyond the "superusers" and providing diabetes care for the broader population. The company's innovative technologies and user-friendly designs aim to make top-quality insulin delivery both affordable and simple to learn.

The company's forward-looking statements, as per the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, are subject to various risks and uncertainties, including the timing of manufacturing line readiness, FDA clearance, market acceptance, and consumer demand. Investors are advised to review these risks and other important factors described in Modular Medical's SEC filings.

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder of Tandem Diabetes and invented and designed its t:slim insulin pump.

References:
[1] https://www.morningstar.com/news/accesswire/1065305msn/modular-medical-announces-completion-of-modd1-cartridge-production-and-commencement-of-pivot-conversion